Strides Pharma sells stake in Pivot Path to Ascent Capital
Strides Pharma Science Limited approved the sale of a majority stake in subsidiary Pivot Path Private Limited to Ascent Capital and Vintage Classic for ~Rs 1,000 million. The transaction includes a primary infusion of ~Rs 500 million into Pivot Path, which will be reclassified as an associate company. Pivot Path contributed 3% to Strides' consolidated turnover in FY 2025-26.
*this image is generated using AI for illustrative purposes only.
Strides Pharma Science Limited has approved the sale of a majority stake in its wholly owned subsidiary, Pivot Path Private Limited, to a consortium led by Ascent Capital and co-investor Vintage Classic. The transaction involves an aggregate consideration of ~Rs 1,000 million for the stake sale and a primary infusion of ~Rs 500 million into Pivot Path by Ascent Capital. Upon completion, Pivot Path will be reclassified as an associate company, reducing Strides' holding to 19.95%, while investors will hold 65.05% and an ESOP Pool will constitute 15%.
The Board of Directors approved the strategic investment at its meeting held on June 27, 2026. The definitive agreements are proposed to be executed before June 30, 2026. The sale of shares is expected to be completed by June 30, 2026, while the primary infusion by Ascent Capital is anticipated to be completed by July 31, 2026.
Pivot Path originated within Arco Lab Private Limited, Strides' Global Capability Centre (GCC), and provides services in life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. The business was carved out into Pivot Path pursuant to a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026. For FY 2025-26 on a post-demerger basis, Pivot Path contributed Rs 1,447 million to the consolidated turnover, representing 3% of Strides' turnover, and Rs 360 million to consolidated net worth, representing 1%.
The consideration for the sale of shares will be received in two tranches: Rs 750 million payable at the initial closing and Rs 250 million payable on the first anniversary of the closing. The transaction is based on an independent valuation conducted by a SEBI-registered merchant banker. The investors, Ascent Growth Trust and Vintage Classic Limited, do not belong to the promoter, promoter group, or group companies of Strides Pharma Science Limited. The proposed transaction is not a related party transaction.
Financial Contribution of Pivot Path
The following table details the contribution of Pivot Path to Strides' financials for FY 2025-26 on a post-demerger basis:
| Particulars | Standalone Basis | Consolidated Basis |
|---|---|---|
| Turnover | Nil | Rs 1,447 million (Contributes 3% to Strides Turnover) |
| Networth | Rs 100 million (Contributes ~0.3% to Strides Networth) | Rs 360 million (Contributes 1% to Strides Networth) |
Transaction Structure
The deal comprises the divestment of a majority stake by Strides and the infusion of primary capital into Pivot Path. The resultant capital structure post-transaction will see Strides retain a 19.95% stake, with investors holding 65.05% and an ESOP Pool accounting for 15%.
Historical Stock Returns for Strides Pharma Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.62% | -2.23% | -6.16% | +15.34% | +29.97% | +224.98% |
How does Strides Pharma plan to utilize the Rs 1,000 million proceeds from the stake sale to strengthen its core business?
What specific growth strategies will the new investors implement to scale Pivot Path's digital transformation capabilities?
How will the deconsolidation of Pivot Path impact Strides' reported revenue and profit margins in the upcoming fiscal year?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
